ProAct - PBM’s Post

Few drug categories have exploded in popularity like the GLP-1s. If you're interested in learning more, join this 3-part webinar series, with the first session kicking off tomorrow 7/18!

GLP-1 agonists have become popular tools in the journey towards weight loss. But with options like Wegovy, Ozempic, and Saxenda, you might be wondering which one is the right fit for you. Watch this video to know .... #WeightLossJourney #GLP1 #WelltopiaPharmacy #healthyliving #weightlossjourney

Who is tired of the GLP-1 rage? NOT ME. You will see the potential if you understand what GLP-1 does in the body and the difference between a GLP-1 agonist (DRUG) and an ingredient that supports its natural production. My latest blog brings you up to speed on GLP-1. https://lnkd.in/ejQtGfW5

How to Preserve Muscle While Using GLP-1 Agonists

Important Reminder📌 MHRA reminds about the negative side effects of GLP-1 agonists and to report any misuse #GLP_1_Agonists #Misuse #Side_effects Read more: https://lnkd.in/dcBVZW4Z

🎄 Happy Holidays from us 🎄 "We are very proud of what we have achieved together on the KL1333 program. It has not been an easy path, but together we have progressed KL1333 through a large Phase 1 program, a strong Phase 1b readout in patients, IND approval, ODD and Fast Track approvals, contracting with commercial manufacturers for the drug product and substance, and successful execution of Wave 1 of the FALCON study and the interim analysis". Wishing you all a fantastic holiday spent with family and friends! Best, The Abliva Team Ellen Donnelly, Dag Nesse, Imen Chamkha, Magnus Hansson, Catharina Johansson, Eskil Elmér, Eleonor Åsander Frostner #mitochondrialdisease #drugdevelopment #raredisease #clinicaltrials #kl1333 #interimanalysis #phase2

This past weekend’s discussion at the #ApsenIdeasFestival on GLP-1s is now live on YouTube. The panel highlights GLP-1s as generational breakthrough medications with positive health and longevity impacts beyond diabetes and weight loss. They explore the potential of a Netflix model (subscription) for access, addressing healthcare challenges by using these drugs preventatively. Check out the discussion here: #GLP1s #NetflixModel

Discover the science behind one of the most exciting and controversial advancements in weight management: GLP-1 receptor agonist medications. In this video, we delve into how these medications aid in weight loss, their mechanism of action, and the potential benefits they offer. We also explore the possible risks and side effects to give you a comprehensive understanding of these treatments.

Many people tend to regain weight after stopping GLP-1 agonists. While these drugs often promote weight loss, a significant portion of that loss is lean mass. When the weight is regained, it’s primarily fat mass—sometimes resulting in a worse body composition than before. The big question: Can GLP-1 agonists be designed to sustain weight loss even after discontinuation?

The vast majority of FDA-approved drugs target proteins. Drug developers typically take aim at small structural grooves on protein surfaces known as binding pockets. Not all of these grooves are made equal, however. Cryptic pockets are like buried treasure. They're mysterious, difficult to find, but come with untold riches once surfaced. In this brief essay, I discuss cryptic binding pockets as well as a new method to decipher them: SWISH-X! https://lnkd.in/edseRVTz